Key clinical point: MRI-guided adaptive brachytherapy yields promising long-term outcomes in locally advanced cervical cancer but needs refinement to reduce morbidity and improve efficacy for certain patients, research suggests.

Major finding: The 5-year rates of local control and overall survival were 92% and 74%, respectively, and 14.6% of patients experienced grade 3-5 treatment-related morbidity.

Study details: A prospective, single-arm cohort study of 1,341 women with stage IB–IVB cervical cancer (EMBRACE I study).

Disclosures: The study was supported by unrestricted grants from Elekta and Varian. Dr. Pötter disclosed no conflicts of interest.